Literature DB >> 23170788

Does the use of fetal fibronectin in an algorithm for preterm labor reduce triage evaluation times?

Gene T Lee1, Richard Burwick, Noelia Zork, Siri Kjos.   

Abstract

OBJECTIVE: To determine the effectiveness of a novel algorithm based on fetal fibronectin (FFN) for management of preterm labor (PTL).
METHODS: A randomized trial was performed on patients who presented with symptoms of PTL at 24-34 weeks. Patients were randomized to algorithms with cervical exams only versus cervical exams plus FFN. In this algorithm, physicians had to discharge patients with a negative FFN result. The primary outcome was the evaluation time for triage. The secondary outcomes were admission to the hospital for PTL, preterm birth <34 weeks and preterm birth <37 weeks.
RESULTS: A total of 76 patients were enrolled and randomized (control n = 32, FFN n = 44). There were no differences in triage time, hospital admissions or preterm deliveries (PTDs) between the two groups.
CONCLUSION: An algorithm based on FFN for management of PTL does not reduce evaluation times for triage, hospital admissions or PTDs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23170788     DOI: 10.3109/14767058.2012.750291

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  3 in total

1.  The utility of fetal fibronectin in asymptomatic singleton and twin pregnancies with a cervical length ≤ 10 mm.

Authors:  Noelia Zork; Moti Gulersen; Anne Mardy; Caroline Pessel; Sara Brubaker; Joy Vink; Cynthia Gyamfi-Bannerman; Cande V Ananth
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-13

2.  Fetal fibronectin testing for reducing the risk of preterm birth.

Authors:  Vincenzo Berghella; Gabriele Saccone
Journal:  Cochrane Database Syst Rev       Date:  2019-07-29

3.  Diagnostic Potential of Evaluation of SDF-1α and sRAGE Levels in Threatened Premature Labor.

Authors:  Rafał Rzepka; Barbara Dołęgowska; Aleksandra Rajewska; Daria Sałata; Marta Budkowska; Sebastian Kwiatkowski; Andrzej Torbé
Journal:  Biomed Res Int       Date:  2016-07-31       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.